688089 logo

Cabio Biotech (Wuhan) XSSC:688089 Stock Report

Last Price

CN¥19.42

Market Cap

CN¥3.3b

7D

-3.6%

1Y

9.0%

Updated

26 Dec, 2024

Data

Company Financials +

Cabio Biotech (Wuhan) Co., Ltd.

XSSC:688089 Stock Report

Market Cap: CN¥3.3b

688089 Stock Overview

Develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. More details

688089 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance3/6
Financial Health5/6
Dividends2/6

Rewards

Price-To-Earnings ratio (28.5x) is below the CN market (35.3x)

Earnings are forecast to grow 22.43% per year

Earnings grew by 144.8% over the past year

Risk Analysis

Highly volatile share price over the past 3 months compared to the CN market

Large one-off items impacting financial results

Dividend of 1.03% is not well covered by free cash flows


My Notes

Capture your thoughts, links and company narrative

Cabio Biotech (Wuhan) Co., Ltd. Competitors

Baotou Dongbao Bio-TechLtd

SZSE:300239

CN¥3.1b

Zhejiang Fulai New MaterialLtd

SHSE:605488

CN¥3.7b

Dymatic ChemicalsInc

SZSE:002054

CN¥2.8b

Sino-High (China)

SZSE:301076

CN¥4.1b

Price History & Performance

Summary of share price highs, lows and changes for Cabio Biotech (Wuhan)
Historical stock prices
Current Share PriceCN¥19.42
52 Week HighCN¥30.12
52 Week LowCN¥9.98
Beta0.61
1 Month Change-9.97%
3 Month Change10.66%
1 Year Change8.98%
3 Year Changen/a
5 Year Changen/a
Change since IPO-44.81%

Recent News & Updates

Recent updates

Shareholder Returns

688089CN ChemicalsCN Market
7D-3.6%-1.6%-0.5%
1Y9.0%-3.7%9.2%

Return vs Industry: 688089 exceeded the CN Chemicals industry which returned -1.4% over the past year.

Return vs Market: 688089 underperformed the CN Market which returned 10.8% over the past year.

Price Volatility

Is 688089's price volatile compared to industry and market?
688089 volatility
688089 Average Weekly Movement13.7%
Chemicals Industry Average Movement8.3%
Market Average Movement8.8%
10% most volatile stocks in CN Market13.0%
10% least volatile stocks in CN Market5.7%

Stable Share Price: 688089's share price has been volatile over the past 3 months compared to the CN market.

Volatility Over Time: 688089's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of CN stocks.

About the Company

FoundedEmployeesCEOWebsite
1999533Dewei Yiwww.cabio.cn

Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. Its products are used in infant formula food, health food, dietary supplements, and other fields for special medical purposes, pet nutrition food, economic animal feed, personal care and cosmetics, and other fields. The company was founded in 1999 and is based in Wuhan, the People’s Republic of China.

Cabio Biotech (Wuhan) Co., Ltd. Fundamentals Summary

How do Cabio Biotech (Wuhan)'s earnings and revenue compare to its market cap?
688089 fundamental statistics
Market capCN¥3.27b
Earnings (TTM)CN¥114.85m
Revenue (TTM)CN¥506.12m

28.5x

P/E Ratio

6.5x

P/S Ratio

Is 688089 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688089 income statement (TTM)
RevenueCN¥506.12m
Cost of RevenueCN¥309.59m
Gross ProfitCN¥196.53m
Other ExpensesCN¥81.68m
EarningsCN¥114.85m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.68
Gross Margin38.83%
Net Profit Margin22.69%
Debt/Equity Ratio1.1%

How did 688089 perform over the long term?

See historical performance and comparison

Dividends

1.0%

Current Dividend Yield

29%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 07:45
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cabio Biotech (Wuhan) Co., Ltd. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wendan WangChina International Capital Corporation Limited
Zhuonan XuChina International Capital Corporation Limited
Yifan DuCitic Securities Co., Ltd.